Michael Jin
Partner @ TSVC
San Francisco, United States
Michael Jin is a Managing Director who serves as the BioMed Group Lead at TEEC Angel Fund. Michael leads the analysis and execution of investment in startups in both US and China with focus on biomedicine, semiconductor, and clean-tech.Michael was the Vice President of Engineering & General Manager of China Technology Center at iWatt(acquired by Dialog Semiconductor at $345M in 2013) since 2006 after it merged with Simple Silicon that he co-founded in 2000. He is currently serving as Board Directors in 7 high-tech startups.Michael holds Ph.D./M.Sc. degrees in Electrical Engineering from Stanford University, California and B.Eng./M.Eng. degrees in Biomedical Engineering from Tsinghua University, Beijing.
- Total investments:
- 15
- Last investment:
- Lead investor:
- 7%
Last updated:
For AI agents: llms.txt
Industries Michael Jin invests in
Stages Michael Jin invests in
Countries Michael Jin invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Health Care 5 (33%)
- Biotechnology 4 (27%)
- Medical 3 (20%)
- Information Technology 3 (20%)
- Internet 2 (13%)
Stage
- Seed 4 (27%)
- Series A 3 (20%)
- Funding Round 3 (20%)
- Series B 2 (13%)
- Angel 1 (7%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Subtle Medical is a healthcare technology company that provides AI-powered medical imaging. Its products, SubtlePET and SubtleMR, are FDA Cleared and CE Marked AI product that enhances images in PET and MR exams aimed for faster & safer workflow.The company's SubtleGAD technology is also awarded by RSNA and a $1.6M NIH SBIR Grant tofacilitate the adoption using AI to make imaging exams safer. They provide a vendor-agnostic AI infrastructure powering its products and providing service and analytics to clinical imaging providers.Subtle Medical's goal is to improve the quality, value, and accessibility of medical imaging by significantly reducing cost, imaging time, and radiation dose. | $12.2M / Series A / Nov 20, 2020 | ||
| iSono Health is transforming breast cancer screening by combining automated ultrasound and artificial intelligence (AI) to empower women and physicians with accessible and personalized breast health monitoring. | $3.5M / Seed / Aug 01, 2019 | ||
| Subtle Medical is a healthcare technology company that provides AI-powered medical imaging. Its products, SubtlePET and SubtleMR, are FDA Cleared and CE Marked AI product that enhances images in PET and MR exams aimed for faster & safer workflow.The company's SubtleGAD technology is also awarded by RSNA and a $1.6M NIH SBIR Grant tofacilitate the adoption using AI to make imaging exams safer. They provide a vendor-agnostic AI infrastructure powering its products and providing service and analytics to clinical imaging providers.Subtle Medical's goal is to improve the quality, value, and accessibility of medical imaging by significantly reducing cost, imaging time, and radiation dose. | $4M / Seed / Jun 01, 2018 | ||
| Subtle Medical is a healthcare technology company that provides AI-powered medical imaging. Its products, SubtlePET and SubtleMR, are FDA Cleared and CE Marked AI product that enhances images in PET and MR exams aimed for faster & safer workflow.The company's SubtleGAD technology is also awarded by RSNA and a $1.6M NIH SBIR Grant tofacilitate the adoption using AI to make imaging exams safer. They provide a vendor-agnostic AI infrastructure powering its products and providing service and analytics to clinical imaging providers.Subtle Medical's goal is to improve the quality, value, and accessibility of medical imaging by significantly reducing cost, imaging time, and radiation dose. | $1.1M / Seed / Sep 01, 2017 | ||
| CureSeq’s mission is to revolutionize next-generation sequencing in the oncology space by making it more affordable, offering faster time to results with a comprehensive solution. They offer products to advance your research endeavors, and will open their services shortly. Turnaround time using their products is 48 hours from extraction throughgenerating clinically relevant mutations. CureSeq’s technology is born out of the Applied Genomics Thoracic Oncology Lab of Dr. Il-Jin Kim at UCSF. | Aug 12, 2016 | ||
| Kolo Medical is a world leader in next generation semiconductor(silicon) ultrasound transducer technology. They are the first company to make Kolo's SiEra (Silicon Era) transducer technology a practical alternative to PZT transducers, thus uniquely positioned to set a new performance standard in clinical diagnostic imaging. Their design andengineering innovations will establish the silicon age of ultrasound imaging.Kolo has brought together a team of world-class talent from the medical ultrasound and semiconductor industries. Their founders, originally from the research group at Stanford University that invented the CMUT technology, have more than 30 years' experience in silicon transducer innovation. Their expertise in developing the most advanced innovations in this field puts Kolo in an enviable position, with more than 40+ patents and impressive IP. Their management team is comprised of seasoned executives and world-renowned technology pioneers from market leading companies, known for their experience in developing and commercializing emerging innovative technologies.Kolo's proprietary transducer technology delivers an unprecedented level of performance in the area of ultra-high resolution imaging. They offer a portfolio of innovative transducers to meet their customers' diagnostic imaging needs and enable new applications in areas that are not currently developed due to limitations of existing PZT transducer technology. | Series B / Mar 10, 2016 | ||
| MyHealthTeams is a San Francisco-based company building deeply engaging social networks for people living chronic conditions. MyHealthTeams is leading the way in patient engagement, making it easy for consumers to find the people, support, and information needed to better manage health outcomes.Eric Peacock & Mary Ray co-founded MyHealthTeamsin 2012. As of 2021, MyHealthTeams has built and operates over 42 social networks to serve 90% of the addressable chronic condition population in 13 countries. | $5M / Series A / Nov 02, 2015 | ||
| NVIGEN is a nanobiotechnology company revolutionizing the field of multifunctional nanoparticles for biomedical applications. Their pipeline of visionary solutions stems from our proprietary nanochemistry technology. NVIGEN was founded in the heart of Silicon Valley, from technologies that culminated from years of rigorous research at theUniversity of California, Berkeley, and Stanford University. NVIGEN develops nanoparticle research reagents and devices for biomedical research applications. NVIGEN was incorporated in 2011. | Feb 18, 2014 | ||
| DataFox is a company intelligence platform that helps sales, marketing, and investing teams find and prioritize target companies to source more opportunities. DataFox's team of 100+ human analysts verify AI-sourced insights on millions of businesses to provide robust Company Data, Growth Signals, and Account Scoring.Headquartered in SanFrancisco, CA, DataFox is backed by Goldman Sachs, Green Visor, Google Ventures, and Slack, and used by high-growth startups and Fortune 500 companies alike; examples include UPS, Accel Partners, Bain & Company, Twilio, Zendesk, and Outreach. | $1.8M / Seed / Oct 01, 2013 | ||
| Valant is a SaaS organization serving the needs of the behavioral healthcare industry. Through disruptive technology solutions, they reinventing the possibilities of how electronic healthcare record (EHR) systems serve the mental health community and its patients. The company's platform utilizes the full power of cloud technology and givesbehavioral healthcare providers the tools to configure their unique workflows.Valant provides the tools they need to automate and enhance patient engagement, outcomes measurement, and revenue. With an intuitive workflow and easy to use dashboards and reports, get more sleep knowing using the best practices for effective practice management. | $783.9K / May 22, 2013 | ||
| See all 15 investments → | |||
Co-Investors
About TSVC
TSV Capital (TSVC), founded in 2010 and formerly known as TEEC Angel Fund, is a leading seed fund specializing in Deeptech, Healthtech, and the Data Economy. As the first seed fund in Silicon Valley established by immigrants from mainland China, TSVC made history as the first institutional investor in Zoom. According to Pitchbook, TSVC is a topperformer in unicorn hit rates from seed investments. TSVC is driven by a team of accomplished entrepreneurs and industry experts. With a visionary approach, TSVC continues to pioneer emerging sectors and fuel future innovation, boasting a track record of 5 IPOs and 10 unicorns from over 200 high-quality investments, including Zoom, Ginkgo Bioworks, Jasper, Carta, Opentrons, Plus, Womply, Iterable, Zūm, and d-matrix.
TSVC Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Charles Shao
General Partner
|
|||
Chiu Chau
Venture Partner
|
|||
Chun Xia
Founding Partner
|
|||
Chun Xia
Founding Partner
|
|||
|
David Duan
Venture Partner
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does Michael Jin invest in?
Michael Jin invests primarily in Health Care, Biotechnology and Medical startups, most often at Seed and Series A stage. Most of the 15 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Michael Jin?
Public channels for Michael Jin include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Michael Jin last invest?
The most recent investment recorded for Michael Jin closed in Nov 2020. Shizune tracks 15 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Sep 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
